中国医科大学学报

中国医科大学学报
  • 中文核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
  • BA、CA收录

中国医科大学学报 ›› 2018, Vol. 47 ›› Issue (8): 740-743,747.doi: 10.12007/j.issn.0258-4646.2018.08.016

• 综述 • 上一篇    下一篇

小细胞肺癌免疫治疗的研究进展

管超, 于莉, 徐兆国, 崔国元, 张晓晔   

  1. 中国医科大学附属盛京医院第四肿瘤科, 沈阳 110022
  • 收稿日期:2017-12-07 出版日期:2018-08-30 发布日期:2018-08-17
  • 通讯作者: 张晓晔 E-mail:zh_yd@126.com
  • 作者简介:管超(1988-),女,医师,硕士.
  • 基金资助:
    国家自然科学基金(61672146)

Development of Immunotherapy for Small Cell Lung Cancer

GUAN Chao, YU Li, XU Zhaoguo, CUI Guoyuan, ZHANG Xiaoye   

  1. The Fourth Oncology Department, Shengjing Hospital, China Medical University, Shenyang 110022, China
  • Received:2017-12-07 Online:2018-08-30 Published:2018-08-17

摘要: 小细胞肺癌(SCLC)起源于肺内的神经内分泌细胞前体,具有高侵袭性,高复发风险,高倍增速度等临床生物学特征。在过去的30年,SCLC基本处于治疗瓶颈期,缺少有效的治疗手段,因此临床迫切渴望推出新型的安全可靠、疗效显著的治疗方法。近期有临床研究结果显示,免疫治疗可能会成为改善SCLC患者预后的一种可选择的治疗手段,但免疫治疗的相关不良反应也不容忽视。本文将对SCLC免疫治疗的机制和免疫治疗药物的最新临床研究、研究结果及不足之处予以综述。

关键词: 小细胞肺癌, 免疫治疗, CTLA-4, PD-1/PD-L1

Abstract: Small cell lung cancer(SCLC) originates from neuroendocrine cell precursors within the bronchi and is characterized by its highly aggressive nature,a high risk of recurrence,and a high proliferation rate. Over the past 3 decades,systemic treatment options for SCLC have undergone few changes in that therapeutic options are limited and have nearly reached the stage of a bottleneck. Therefore,safe and novel therapies are urgently needed in clinical practice. Recently,clinical research has shown that immunotherapy may be a feasible treatment approach that could improve the prognosis in patients with SCLC. This article will review the mechanism of immunotherapy,the recent clinical research results,and the deficiencies in SCLC.

Key words: small cell lung cancer, immunotherapy, CTLA-4, PD-1/PD-L1

中图分类号: 

  • R734.2
[1] RUDIN CM,ISMAILA N,HANN CL,et al.Treatment of small-cell lung cancer:American society of clinical oncology endorsement of the american college of chest physicians guideline[J].J Clin Oncol, 2015,33(34):4106-4111.DOI:10.1200/JOP.2015.008201.
[2] FR H M,DE RUYSSCHER D,POPAT S,et al.Small-cell lung cancer (SCLC):ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2013,24(suppl 6):vi99-vi105.DOI:10.1093/annonc/mdt178.
[3] VESELY MD,KERSHAW MH,SCHREIBER RD,et al.Natural innate and adaptive immunity to cancer[J].Annu Rev Immunol,2011, 29(1):235-271.DOI:10.1146/annurev-immunol-031210-101324.
[4] WANG W,HODKINSON P,MCLAREN F,et al.Histologic assessment of tumor-associated CD45(1) cell numbers is an independent predictor of prognosis in small cell lung cancer[J].Chest,2013,143(1):146-151.DOI:10.1378/chest.12-0681.
[5] RIZVI NA,HELLMANN MD,SNYDER A,et al.Cancer immunology.Mutational landscape determines sensitivity to PD-1 blockade in nonsmall cell lung cancer[J].Science,2015,348(6230):124-128.DOI:10.1126/science.aaa1348.
[6] PARDOLL DM.The blockade of immune checkpoints in cancer immunotherapy[J].Nat Rev Cancer,2012,12(6):252-264.DOI:10.1038/nrc3239.
[7] HODI FS,O'DAY SJ,MCDERMOTT DF,et al.Improved survival with ipilimumab in patients with metastatic melanoma[J].N Engl J Med,2010,363(8):711-723.DOI:10.1056/NEJMoa1003466.
[8] ROBERT C,THOMAS L,BONDARENKO I,et al.Ipilimumab plus dacarbazine for previously untreated metastatic melanoma[J].N Engl J Med,2011,364(26):2517-2526.DOI:10.1056/NEJMoa1104621.
[9] LEE F,JURE-KUNKEL MN,SALVATI ME.Synergistic activity of ixabepilone plus other anticancer agents:preclinical and clinical evidence[J].Ther Adv Med Oncol,2011,3(1):11-25.DOI:10.1177/1758834010386402.
[10] DONG H,STROME SE,SALOMAO DR,et al.Tumor-associated B7-H1 promotes T-cell apoptosis:a potential mechanism of immune evasion[J].Nat Med,2002,8(8):793-800.DOI:10.1038/nm730.
[11] WANG A,WANG HY,LIU Y,et al.The prognostic value of PD-L1 expression for non-small cell lung cancer patients:a meta-analysis[J].Eur J Surg Oncol,2015,41(4):450-456.DOI:10.1016/j.ejso.2015.01.020.
[12] CHANG YL,YANG CY,LIN MW,et al.High co-expression of PDL1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma[J].Eur J Cancer,2016,60(1):125-135.DOI:10.1016/j.ejca.2016.03.012.
[13] OKUMA HS,HORINOUCHI H,KITAHARA S,et al.Comparison of amrubicin and weekly cisplatin/etoposide/irinotecan in patients with relapsed smallcell lung cancer[J].Clin Lung Cancer,2017,18(2):234-240.DOI:10.1016/j.cllc.2016.09.005.
[14] BRONTE G,RIZZO S,LA PAGLIA L,et al.Driver mutations and differential sensitivity to targeted therapies:a new approach to the treatment of lung adenocarcinoma[J].Cancer Treat Rev,2010,36(Suppl 3):S21-S29.DOI:10.1016/S0305-7372(10)70016-5.
[15] ANTONIA SJ,LOPEZ-MARTIN JA,BENDELL J,et al.Nivolumab aloneand nivolumab plus ipilimumab in recurrent small-cell lung cancer(CheckMate 032):a multicentre,open-label,phase 1/2 trial[J].Lancet Oncol,2016,17(7):883-895.DOI:10.1016/S1470-2045(16)30098-5.
[16] ASAI N,OHKUNI Y,KANEKO N,et al.Relapsed small-cell lung cancer:treatment options and latest developments[J].Ther Adv Med Oncol,2014,6(2):69-82.DOI:10.1177/1758834013517413.
[17] OTT P,FELIP E,HIRET S OA,et al.Pembrolizumab in patients with extensive-stage small cell lung cancer:updated survival results from KEYNOTE 028[J].J Thorac Oncol,2017,12(1):S259.DOI:10.1200/JCO.2017.72.5069.
[18] PARK JJ,OMIYA R,MATSUMURA Y,et al.B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance[J].Blood,2010,116(8):1291-1298.DOI:10.1182/blood-2010-01-265975.
[1] 王倩文, 徐振华, 王志静, 苏荣健, 陈学军, 谷艳娇. 葡萄糖调节蛋白78对L858R突变的非小细胞肺癌erlotinib敏感性的影响[J]. 中国医科大学学报, 2018, 47(8): 701-704.
[2] 张苏宁, 刘宗昂. 小细胞肺癌中DBC1的表达及预后相关性研究[J]. 中国医科大学学报, 2018, 47(3): 222-225.
[3] 赵轲, 张永建, 刘奇, 徐迪, 陈宝钧. miR-107与非小细胞肺癌的临床病理特征及预后的关联[J]. 中国医科大学学报, 2018, 47(10): 933-938.
[4] 金波,刘云鹏. 老年小细胞肺癌的治疗进展[J]. 中国医科大学学报, 2017, 46(8): 750-753.
[5] 周立霞,吴月明,李娜. 色素上皮源性因子通过血管内皮生长因子抑制 非小细胞肺癌的发生发展[J]. 中国医科大学学报, 2017, 46(5): 422-424.
[6] 于溪 ,张彬彬 ,杨碧洁 ,张哲 ,马铭霞 ,邹佳运 ,赵明芳. 乳酸脱氢酶和神经元特异性烯醇化酶水平与广泛期小细胞肺癌 预后的关系[J]. 中国医科大学学报, 2017, 46(5): 425-428.
[7] 李向敏,许瑶琳,于莉,齐晓莹,蒋中秀,张晓晔. 52 例小细胞肺癌免疫组化表型的临床特点分析[J]. 中国医科大学学报, 2017, 46(5): 460-462.
[8] 于溪 ,张彬彬 ,于溪 ,杨碧洁 ,张哲 ,马铭霞 ,邹佳运 ,赵明芳. 血红蛋白和胆红素水平与广泛期小细胞肺癌预后的关系[J]. 中国医科大学学报, 2017, 46(2): 112-115.
[9] 贺政, 李光, 张宏伟, 张硕. 1H磁共振波谱在非小细胞肺癌脑转移放疗疗效评价中的预测价值[J]. 中国医科大学学报, 2017, 46(12): 1095-1100.
[10] 袁梦, 韩琤波, 马洁韬, 黄乐天, 张树玲, 孙丽. 不可手术局部晚期非小细胞肺癌放化疗安全性及疗效分析[J]. 中国医科大学学报, 2017, 46(12): 1124-1128.
[11] 栾岚,张天戈,韩斌,罗文婷,吴非,廖鑫,张君杰,白阳,程新宇,滕猛,王翠芳. miR-218-1-3p对非小细胞肺癌细胞增殖、周期及凋亡的影响[J]. 中国医科大学学报, 2017, 46(11): 980-983.
[12] 姜西子,金艾琳,马琳,唐娜,张清富,孙丽梅,邱雪杉. 非小细胞肺癌中PHF20与凋亡相关蛋白Bax的表达及相关性[J]. 中国医科大学学报, 2017, 46(10): 887-890.
[13] 王园,田野,刘思洋,赵希彤,姜文军,田大力. 血管内皮生长因子及其受体在伴恶性胸腔积液非小细胞肺癌组织中的表达[J]. 中国医科大学学报, 2016, 45(5): 441-444.
[14] 李秀琳,韩冲,唐玲荣,于洋洋,党军,李楠,李光. 非小细胞肺癌 hMOF 蛋白表达与放疗预后的关系[J]. 中国医科大学学报, 2016, 45(4): 340-344.
[15] 张树玲,孙鑫,孙丽,熊志成,孙婧,马洁韬,韩琤波. EGFR 激活突变型非小细胞肺癌 HGF/MET 异质性表达及其临床意义[J]. 中国医科大学学报, 2016, 45(10): 865-870.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!

中国医科大学学报版权所有©2018

未经允许,严禁擅自转载本站图文资料

地址:中国 沈阳市沈北新区蒲河路77号 110122

辽ICP备05014850

JOURNAL OF CHINA MEDICAL UNIVERSITY

ADDRESS: NO.77 PUHE ROAD

SHENYANG NORTH NEW AREA, SHENYANG

LIAONING PROVINCE, P.R. CHINA